AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Net Periodic OPEB Cost: $58M in FY2025, down 10.8% from a year earlier.
Latest, FY2025
58
Period ended Dec 31, 2025
Change on a year earlier
-10.8%
65 in FY2024
History
11 years
Since FY2015
Sources
9
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Post-Employment Benefits Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Periodic OPEB Cost ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 58 | -10.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 65 | +30.0% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | 50 | -19.4% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 62 | +3.3% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 60 | -38.8% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | 98 | +78.2% | Form 10-K (filed 2023-02-17) ↗ |
| FY2019 | Dec 31, 2019 | 55 | +5.8% | Form 10-K (filed 2022-02-18) ↗ |
| FY2018 | Dec 31, 2018 | 52 | +4.0% | Form 10-K (filed 2021-02-19) ↗ |
| FY2017 | Dec 31, 2017 | 50 | +2.0% | Form 10-K (filed 2020-02-21) ↗ |
| FY2016 | Dec 31, 2016 | 49 | -2.0% | Form 10-K (filed 2019-02-27) ↗ |
| FY2015 | Dec 31, 2015 | 50 | – | Form 10-K (filed 2018-02-16) ↗ |
Cite this data
StockData. (2026). AbbVie Net Periodic OPEB Cost ($M), annual FY2015–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/db-opeb-net-cost
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.